Materials and methods
Chemicals were of analytic grade and used as received. Na 125 I was purchased from MP Biomedical LLC. 1 H NMR spectra were measured using a Varian UNITY 400 (400 MHz) or a Varian Mercury 300 (300 MHz) or a Bruker ascend 600 (600 MHz) spectrometer. Chemical shifts are reported as ppm (in or CDCl 3 ). Mass spectra (MS) were recorded on a Waters LCT Premier XE system. HRMS were recorded using an Applied Biosystems Mariner System 5299 spectrometer. All melting points were determined using a Yanaco melting point apparatus (Yanagimoto Ind. Co., Kyoto, Japan) and are uncorrected. Infrared (IR) spectra were recorded in potassium bromide pellets using a Shimadzu-FT-IR 8400. HPLC analyses were performed using a Shimadzu LC-6AD equipped with a Shimadzu SPD-10A UV detector, a Shimadzu LC-6A equipped with a Shimadzu SPD-6A UV detector and a EG&G 40101A radioactivity detector, or a GL Science GL-7540 equipped with a Perkin Elmer FSA 505TR radioactivity detector.
Chemistry (2-Bromo-4-nitrophenyl)hydrazine (2)
To a solution of 2-bromo-1-fluoro-4-nitrobenzene (325 mg, 1.5 mmol) in EtOH (10 mL), hydrazine hydrate was slowly added (75 mg, 1.5 mmol) over 15 min at 85°C. The solution was stirred for 1.5 h at 85°C and then allowed to cool to room temperature. The 
Ethyl 1-(4-amino-2-(tributylstannyl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (5)
To a solution of 4 (1.13 g, 3.0 mmol) in toluene (5.0 mL), bis(tri-n-butyltin) (3.0 mL, 
Ethyl 1-(4-amino-2-iodophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (6)
To a solution of 5 (59 mg, 0.10 mmol) in CH 2 Cl 2 (3.4 mL), 0. A mixture of thionyl chloride (9 mL, 124 mmol) and trichloroacrylic acid (515 mg, 2.96 mmol) was stirred at 75°C for 16.5 h. After the solution was concentrated in vacuo, the resulting mixture was diluted with CH 2 Cl 2 . A solution of 5 (572 mg, 1.0 mmol) in CH 2 Cl 2 and N,N-diisopropylethylamine (0.5 mL, 2.91 mmol) were added to the mixture and the solution was stirred at 0°C for 2.5 h. After water was added to the reaction mixture, the mixture was extracted with CH 2 Cl 2 , and the combined organic layers were dried over anhydrous Na 2 SO 4 and concentrated in vacuo. 
Ethyl 1-(2-iodo-4-(2,3,3-trichloroacrylamido)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (I-Pyr3)
A mixture of thionyl chloride (3 mL, 41 mmol) and trichloroacrylic acid (164 mg, 0.94 mmol) was stirred at room temperature for 15 min, and then slowly warmed to 75°C. After the solution was stirred for 6.5 h, thionyl chloride (3 mL, 41 mmol) was added and the solution was stirred for 30 min. After the solution was concentrated in vacuo, the resulting mixture was diluted with CH 2 Cl 2 . Added to the mixture was a solution of 6 (132 mg, 0.31 mmol) in CH 2 Cl 2 and N,N-diisopropylethylamine (0.1 mL, 0.31 mmol), and the solution was stirred at 0°C for 1 h. After water was added to the reaction mixture, the mixture was extracted with CH 2 Cl 2 , and the combined organic layer was dried over anhydrous Na 2 SO 4 , and concentrated in vacuo. Purification by column chromatography on silica gel (hexane/EtOAc 3/1) gave I-Pyr3 (139 mg, 60% 160.7, 157.9, 143.0, 139.0, 138.9, 130.2, 129.4, 128.5, 122.8, 120.0, 119.7, 117.9, 116.5, 96.7, 61.4, 14 -4-(2,3,3-trichloroacrylamido) .
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Preparation of [ 125 I]I-Pyr8
To a solution of [ 125 I]I-Pyr3 (500 μL, 0.52 MBq) in methanol/H 2 O (3/1), a solution of 1M NaOH (50 μL) was added. The reaction mixture was incubated for 30 min at 50°C.
The product was purified using HPLC on a 4.6 × 250 mm COSMOSIL 5C18-ARⅡ column eluted with acetonitrile and water containing 0.1% TFA (65:35) at a flow rate of 0.9 mL/min. 
In vivo biodistribution in normal mice
In vivo biodistribution studies were approved by the Kobe Pharmaceutical University 
